DAY 3 – November 13, 2009

SESSION IV: Myeloproliferative Disease: Mechanisms and Targets – Ayalew Tefferi, MD, Moderator

8:00–8:20

Molecular Biology of MPD

Ross L. Levine, MD

8:20–8:40

Modulating Megakaryocyte Development as a Therapeutic Strategy

John Crispino, PhD

8:40–9:00

MPD Consortium Clinical Trials

Ronald Hoffman, MD

9:00–9:20

How and When to Use Kinase Inhibitors in MPD

Ayalew Tefferi, MD

9:20–9:40

Discussion–Is JAK2 the Whole Story?

Josef T. Prchal, MD

9:40–10:10

Discussion

10:10–10:30

Break

Session V: Multiple Myeloma: Mechanisms and Targets – Kenneth C. Anderson, MD, Moderator

10:30–10:50

Molecular Pathogenesis of Myeloma

P. Leif Bergsagel, MD

10:50–11:10

Transcriptional Deregulation in Myeloma

John D.Shaughnessy, PhD

11:10–11:30

Epigenetic Changes in Myeloma

Jonathan D. Licht, MD

11:30–11:50

Glucocorticoid Resistance in Myeloma

Steven T. Rosen, MD

11:50–12:10

Discussion–Integration of New Targets in Myeloma

Kenneth C. Anderson, MD

12:10–12:40

Discussion

12:40–2:00

Lunch/Poster Walk

Session VI: Lymphoma and Lymphoproliferative Disease: Mechanisms and Targets – Steven T. Rosen, MD, Moderator

2:00–2:20

EVI1 in MDS

TBD

2:20–2:40

BCL6 and the Genesis of Lymphoma

Riccardo Dalla-Favera, MD

2:40–3:00

Transcriptional Profiling and NFκB

Louis M. Staudt, MD, PhD

3:00–3:20

Transcriptional Targeting

Ari Melnick, MD

3:20–3:40

HDAC Therapy for Lymphoid Disease

Owen A. O'Connor, MD, PhD

3:40–4:00

Bortezomib and Combinations

Robert Z. Orlowski, MD, PhD

4:00–4:30

Discussion

Day 1 AgendaDay 2 AgendaDay 4 AgendaBack to Top